miR-1-3p suppresses the epithelial-mesenchymal transition property in renal cell cancer by downregulating Fibronectin 1

References

• Bukowski RM. Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab. Cancer Manag Res. 2010;2:83–96.21188099
   PubMedGoogle Scholar
• Speed JM, Trinh QD, Choueiri TK, Sun M. Recurrence in localized renal cell carcinoma: a systematic review of contemporary data. Curr Urol Rep. 2017;18:15. doi:10.1007/s11934-017-0661-328213859
   PubMed Web of Science ®Google Scholar
• Abel EJ, Margulis V, Bauman TM, et al. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. BJU Int. 2016;117:E87–E94. doi:10.1111/bju.1326826305276
   PubMed Web of Science ®Google Scholar
• He H, Magi-Galluzzi C. Epithelial-to-mesenchymal transition in renal neoplasms. Adv Anat Pathol. 2014;21:174–180. doi:10.1097/PAP.000000000000001824713987
   PubMed Web of Science ®Google Scholar
• Sciacovelli M, Frezza C. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. Febs J. 2017;284:3132–3144. doi:10.1111/febs.1409028444969
   PubMed Web of Science ®Google Scholar
• Lo UG, Lee CF, Lee MS, Hsieh JT. The role and mechanism of epithelial-to-mesenchymal transition in prostate cancer progression. Int J Mol Sci. 2017;18. doi:10.3390/ijms18102079.
   Web of Science ®Google Scholar
• Wang J, Ou J, Guo Y, et al. TBLR1 is a novel prognostic marker and promotes epithelial-mesenchymal transition in cervical cancer. Br J Cancer. 2014;111:112–124. doi:10.1038/bjc.2014.27824874481
   PubMed Web of Science ®Google Scholar
• Guo Y, Wu Z, Shen S, et al. Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy. Nat Commun. 2018;9:3430. doi:10.1038/s41467-018-05764-730143633
   PubMed Web of Science ®Google Scholar
• Phillips S, Kuperwasser C. SLUG: critical regulator of epithelial cell identity in breast development and cancer. Cell Adh Migr. 2014;8:578–587. doi:10.4161/19336918.2014.97274025482617
   PubMed Web of Science ®Google Scholar
• Wong S, Fang CM, Chuah LH, Leong CO, Ngai SC. E-cadherin: its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 2018;121:11–22. doi:10.1016/j.critrevonc.2017.11.01029279096
   PubMed Web of Science ®Google Scholar
• Harada K, Miyake H, Kusuda Y, Fujisawa M. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int. 2012;110:E1131–E1137. doi:10.1111/j.1464-410X.2012.11297.x22712620
   PubMed Web of Science ®Google Scholar
• Chipman LB, Pasquinelli AE. miRNA Targeting: growing beyond the Seed. Trends Genet. 2019;35:215–222. doi:10.1016/j.tig.2018.12.00530638669
   PubMed Web of Science ®Google Scholar
• Xie M, Lv Y, Liu Z, et al. Identification and validation of a four-miRNA (miRNA-21-5p, miRNA-9-5p, miR-149-5p, and miRNA-30b-5p) prognosis signature in clear cell renal cell carcinoma. Cancer Manag Res. 2018;10:5759–5766. doi:10.2147/CMAR.S18710930532596
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang L, Mao S, et al. miR-1-3p contributes to cell proliferation and invasion by targeting glutaminase in bladder cancer cells. Cell Physiol Biochem. 2018;51:513–527. doi:10.1159/00049527330458442
   PubMedGoogle Scholar
• Li SM, Wu HL, Yu X, et al. The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1. J Exp Clin Cancer Res. 2018;37:219. doi:10.1186/s13046-018-0895-z30185212
   PubMed Web of Science ®Google Scholar
• Ahrend H, Kaul A, Ziegler S, et al. MicroRNA-1 and MicroRNA-21 individually regulate cellular growth of non-malignant and malignant renal cells. In Vivo. 2017;31:625–630. doi:10.21873/invivo.1110328652429
   PubMed Web of Science ®Google Scholar
• Kawakami K, Enokida H, Chiyomaru T, et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer. 2012;48:827–836. doi:10.1016/j.ejca.2011.06.03021745735
   PubMed Web of Science ®Google Scholar
• Ren K, Li Y, Lu H, et al. Long noncoding RNA HOTAIR controls cell cycle by functioning as a competing endogenous rna in esophageal squamous cell carcinoma. Transl Oncol. 2016;9:489–497. doi:10.1016/j.tranon.2016.09.00527816685
   PubMed Web of Science ®Google Scholar
• Di W, Li Q, Shen W, Guo H, Zhao S. The long non-coding RNA HOTAIR promotes thyroid cancer cell growth, invasion and migration through the miR-1-CCND2 axis. Am J Cancer Res. 2017;7:1298–1309.28670492
   PubMed Web of Science ®Google Scholar
• Li L, Sarver AL, Alamgir S, Subramanian S. Downregulation of microRNAs miR-1, −206 and −29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma. Lab Invest. 2012;92:571–583. doi:10.1038/labinvest.2012.1022330340
   PubMed Web of Science ®Google Scholar
• Jiang S, Zhao C, Yang X, et al. miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression. Int J Mol Med. 2016;38:113–122. doi:10.3892/ijmm.2016.261927247259
   PubMed Web of Science ®Google Scholar
• Xiao H, Zeng J, Li H, et al. MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. Oncotarget. 2015;6:13201–13215. doi:10.18632/oncotarget.391526036633
   PubMedGoogle Scholar
• Leone V, D’Angelo D, Rubio I, et al. MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. J Clin Endocrinol Metab. 2011;96:E1388–E1398. doi:10.1210/jc.2011-034521752897
   PubMed Web of Science ®Google Scholar
• Gong B, Hu H, Chen J, et al. Caprin-1 is a novel microRNA-223 target for regulating the proliferation and invasion of human breast cancer cells. Biomed Pharmacother. 2013;67:629–636. doi:10.1016/j.biopha.2013.06.00623953883
   PubMed Web of Science ®Google Scholar
• Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci. 2008;29:302–313. doi:10.1016/j.tips.2008.03.00318423896
   PubMed Web of Science ®Google Scholar
• Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15:122. doi:10.1186/gb418425180339
   PubMed Web of Science ®Google Scholar
• Morales F, Giordano A. Overview of CDK9 as a target in cancer research. Cell Cycle. 2016;15:519–527. doi:10.1080/15384101.2016.113818626766294
   PubMed Web of Science ®Google Scholar
• Guo Y, Chen W, Wang W, et al. Simultaneous diagnosis and gene therapy of immuno-rejection in rat allogeneic heart transplantation model using a T-cell-targeted theranostic nanosystem. ACS Nano. 2012;6:10646–10657. doi:10.1021/nn303757323189971
   PubMed Web of Science ®Google Scholar
• Wang J, Jia H, Zhang B, et al. HucMSC exosome-transported 14-3-3zeta prevents the injury of cisplatin to HK-2 cells by inducing autophagy in vitro. Cytotherapy. 2018;20:29–44. doi:10.1016/j.jcyt.2017.08.00228943243
   PubMed Web of Science ®Google Scholar
• Li C, Wu J, Li Y, Xing G. Cytoprotective effect of heat shock protein 27 against lipopolysaccharide-induced apoptosis of renal epithelial HK-2 cells. Cell Physiol Biochem. 2017;41:2211–2220. doi:10.1159/00047563628448995
   PubMedGoogle Scholar
• Qiang S, Du ZF, Huang M. Adenovirus-mediated NDRG2 inhibits the proliferation of human renal cell carcinoma cell line OS-RC-2 in vitro. Asian Pac J Trop Med. 2014;7:873–878. doi:10.1016/S1995-7645(14)60152-825441986
   PubMed Web of Science ®Google Scholar
• Liao H, Wu Z, Huang X, Qiu Z, Wu H. NMyc downstreamregulated gene 2 suppresses proliferation and induces oncosis of OSRC2 human renal cancer cells. Mol Med Rep. 2015;11:1240–1245. doi:10.3892/mmr.2014.288225373306
   PubMed Web of Science ®Google Scholar
• Yang H, Song E, Shen G, et al. Expression of microRNA-30c via lentivirus vector inhibits the proliferation and enhances the sensitivity of highly aggressive ccRCC Caki-1 cells to anticancer agents. Onco Targets Ther. 2017;10:579–590. doi:10.2147/OTT.S11579128203091
   PubMed Web of Science ®Google Scholar
• Liu Y, Fu QZ, Pu L, et al. Effect of RNA interference of the expression of HMGA2 on the proliferation and invasion ability of ACHN renal cell carcinoma cells. Mol Med Rep. 2017;16:5107–5112. doi:10.3892/mmr.2017.725828849119
   PubMed Web of Science ®Google Scholar
• Huang B, Huang YJ, Yao ZJ, et al. Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P. PLoS One. 2013;8:e68293. doi:10.1371/journal.pone.006829323874578
   PubMedGoogle Scholar
• Hyun PW, Hee CY, Won JC, et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun. 2003;300:230–235.12480548
   PubMed Web of Science ®Google Scholar
• Okada SL, Simmons RM, Franke-Welch S, et al. Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype. Cell Immunol. 2018;323:49–58. doi:10.1016/j.cellimm.2017.10.01429103587
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhao J, Qiu M, et al. CRISPR/Cas9 mediated GFP Knock-in at the MAP1LC3B locus in 293FT cells is better for bona fide monitoring cellular autophagy. Biotechnol J. 2018;13:e1700674. doi:10.1002/biot.20170067429673078
   PubMed Web of Science ®Google Scholar
• Shi GH, Ye DW, Yao XD, et al. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin. 2010;31:867–873. doi:10.1038/aps.2010.4820581857
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang J, Li H, et al. Mediator subunit 23 overexpression as a novel target for suppressing proliferation and tumorigenesis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30:1094–1103. doi:10.1111/jgh.1292325684393
   PubMed Web of Science ®Google Scholar
• Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research techniques made simple: analysis of collective cell migration using the wound healing assay. J Invest Dermatol. 2017;137:e11–e16. doi:10.1016/j.jid.2016.11.02028110712
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang J, Zhang L, et al. Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma. Hepatology. 2016;63:1240–1255. doi:10.1002/hep.2840926680504
   PubMed Web of Science ®Google Scholar
• Prante BC, Garman KL, Sims BN, Lindsey JS. Matrix-coated transwell-cultured TM4 sertoli cell testosterone-regulated gene expression mimics in vivo expression. In Vitro Cell Dev Biol Anim. 2008;44:434–443. doi:10.1007/s11626-008-9135-818810563
   PubMed Web of Science ®Google Scholar
• Liu L, Wu J, Guo Y, et al. Overexpression of FoxM1 predicts poor prognosis of intrahepatic cholangiocarcinoma. Aging (Albany NY). 2018;10:4120–4140. doi:10.18632/aging.10170630580327
   PubMedGoogle Scholar
• Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008;36:D149–D153. doi:10.1093/nar/gkm99518158296
   PubMed Web of Science ®Google Scholar
• Garcia DM, Baek D, Shin C, et al. Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol. 2011;18:1139–1146. doi:10.1038/nsmb.211521909094
   PubMed Web of Science ®Google Scholar
• Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4. doi:10.7554/eLife.05005.
   Web of Science ®Google Scholar
• Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105. doi:10.1101/gr.082701.10818955434
   PubMed Web of Science ®Google Scholar
• Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495–500. doi:10.1038/ng153615806104
   PubMed Web of Science ®Google Scholar
• Chen K, Rajewsky N. Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet. 2006;38:1452–1456. doi:10.1038/ng191017072316
   PubMed Web of Science ®Google Scholar
• Wang C, Guo Y, Wang J, Min Z. The suppressive role of SOX7 in hepatocarcinogenesis. PLoS One. 2014;9:e97433. doi:10.1371/journal.pone.009743324816720
   PubMed Web of Science ®Google Scholar
• Zhang T, Liu W, Zeng XC, et al. Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma. Biomed Pharmacother. 2016;84:583–591. doi:10.1016/j.biopha.2016.09.05627694002
   PubMed Web of Science ®Google Scholar
• Guo R, Wu Z, Wang J, et al. Development of a non‐coding‐RNA‐based EMT/CSC inhibitory nanomedicine for in vivo treatment and monitoring of HCC. Adv Sci. 2019. doi:10.1002/advs.201801885
   Web of Science ®Google Scholar
• Jiao D, Chen J, Li Y, et al. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT. J Cell Mol Med. 2018;22:3526–3536. doi:10.1111/jcmm.1362929664235
   PubMed Web of Science ®Google Scholar
• Wang JY, Huang JC, Chen G, Wei DM. Expression level and potential target pathways of miR-1-3p in colorectal carcinoma based on 645 cases from 9 microarray datasets. Mol Med Rep. 2018;17:5013–5020. doi:10.3892/mmr.2018.853229393467
   PubMed Web of Science ®Google Scholar
• Gao L, Yan P, Guo FF, Liu HJ, Zhao ZF. MiR-1-3p inhibits cell proliferation and invasion by regulating BDNF-TrkB signaling pathway in bladder cancer. Neoplasma. 2018;65:89–96. doi:10.4149/neo_2018_161128N59429322793
   PubMed Web of Science ®Google Scholar
• Wang W, Shen F, Wang C, et al. MiR-1-3p inhibits the proliferation and invasion of bladder cancer cells by suppressing CCL2 expression. Tumour Biol. 2017;39:1393391281. doi:10.1177/1010428317698383
   Google Scholar
• Liu W, Li H, Wang Y, et al. MiR-30b-5p functions as a tumor suppressor in cell proliferation, metastasis and epithelial-to-mesenchymal transition by targeting G-protein subunit alpha-13 in renal cell carcinoma. Gene. 2017;626:275–281. doi:10.1016/j.gene.2017.05.04028536082
   PubMed Web of Science ®Google Scholar
• Yamasaki T, Seki N, Yamada Y, et al. Tumor suppressive microRNA138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. Int J Oncol. 2012;41:805–817. doi:10.3892/ijo.2012.154322766839
   PubMed Web of Science ®Google Scholar
• Chaves KC, Turaca LT, Pesquero JB, et al. Fibronectin expression is decreased in metastatic renal cell carcinoma following endostatin gene therapy. Biomed Pharmacother. 2012;66:464–468. doi:10.1016/j.biopha.2012.04.00322920414
   PubMed Web of Science ®Google Scholar
• Kondisetty S, Menon KN, Pooleri GK. Fibronectin protein expression in renal cell carcinoma in correlation with clinical stage of tumour. Biomark Res. 2018;6:23. doi:10.1186/s40364-018-0137-830009029
   PubMed Web of Science ®Google Scholar
• Knowles LM, Gurski LA, Engel C, et al. Integrin alphavbeta3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis. Cancer Res. 2013;73:6175–6184. doi:10.1158/0008-5472.CAN-13-060223966293
   PubMed Web of Science ®Google Scholar
• Bolos V, Peinado H, Perez-Moreno MA, et al. The transcription factor slug represses e-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with snail and E47 repressors. J Cell Sci. 2003;116:499–511.12508111
   PubMed Web of Science ®Google Scholar
• Sheng L, Zhang S, Xu H. Effect of slug-mediated down-regulation of E-cadherin on invasiveness and metastasis of anaplastic thyroid cancer cells. Med Sci Monit. 2017;23:138–143.28070118
   PubMed Web of Science ®Google Scholar
• Wallesch M, Pachow D, Blucher C, et al. Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas. J Neurol Sci. 2017;380:112–121. doi:10.1016/j.jns.2017.07.00928870549
   PubMed Web of Science ®Google Scholar
• Li Z, Liu H, Zhong Q, Wu J, Tang Z. LncRNA UCA1 is necessary for TGF-beta-induced epithelial-mesenchymal transition and stemness via acting as a ceRNA for Slug in glioma cells. FEBS Open Bio. 2018;8:1855–1865. doi:10.1002/2211-5463.12533
   PubMed Web of Science ®Google Scholar
• Peng CY, Liao YW, Lu MY, et al. Downregulation of miR-1 enhances tumorigenicity and invasiveness in oral squamous cell carcinomas. J Formos Med Assoc. 2017;116:782–789. doi:10.1016/j.jfma.2016.12.00328089494
   PubMed Web of Science ®Google Scholar
• Osaka E, Yang X, Shen JK, et al. MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug. J Orthop Res. 2014;32:1075–1082. doi:10.1002/jor.2263224760686
   PubMed Web of Science ®Google Scholar
• Tominaga E, Yuasa K, Shimazaki S, Hijikata T. MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties. Exp Cell Res. 2013;319:77–88. doi:10.1016/j.yexcr.2012.10.01523142026
   PubMed Web of Science ®Google Scholar
• Liu YN, Yin JJ, Abou-Kheir W, et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene. 2013;32:296–306. doi:10.1038/onc.2012.5822370643
   PubMed Web of Science ®Google Scholar
• Waalkes S, Atschekzei F, Kramer MW, et al. Fibronectin 1 mRNA expression correlates with advanced disease in renalcancer. BMC Cancer. 2010;10:503. doi:10.1186/1471-2407-10-50320860816
   PubMed Web of Science ®Google Scholar
• Chen D, Gassenmaier M, Maruschke M, et al. Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma. J Urol. 2014;191:479–486. doi:10.1016/j.juro.2013.08.05224012533
   PubMed Web of Science ®Google Scholar
• Steffens S, Schrader AJ, Vetter G, et al. Fibronectin 1 protein expression in clear cell renal cell carcinoma. Oncol Lett. 2012;3:787–790. doi:10.3892/ol.2012.56622740994
   PubMed Web of Science ®Google Scholar
• Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59:111–137. doi:10.3322/caac.2000319278961
   PubMed Web of Science ®Google Scholar
• Guo R, Wu Z, Wang J, et al. Development of a Non‐Coding‐RNA‐based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC. Advanced Science. 2019; 6:1801885. doi:10.1002/advs.20180188531065520
   PubMed Web of Science ®Google Scholar